Peptides AcademyMulti-Receptor Metabolic Peptides
Dual GIP/GLP-1 and triple GIP/GLP-1/glucagon agonists — Tirzepatide, Retatrutide — the next-generation of metabolic peptides.
Dual & Triple Agonists (Tirzepatide Class) (4)
Maridebart Cafraglutide (MariTide)
Amgen
An investigational antibody-peptide conjugate from Amgen that pairs GLP-1 receptor agonism with GIP receptor antagonism, engineered for infrequent (roughly monthly) dosing in obesity and type 2 diabetes.
Retatrutide
Eli Lilly (investigational)
An investigational triple GIP / GLP-1 / glucagon receptor agonist from Eli Lilly. In the phase 3 TRIUMPH-1 trial, adults with obesity on 12 mg weekly lost a mean 25.0% of body weight at 80 weeks (vs 3.9% on placebo). Not FDA-approved.
Tirzepatide
Mounjaro / Zepbound
First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.
VK2735
Viking Therapeutics
An investigational dual GIP and GLP-1 receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity, with early-phase weight-loss data that has drawn intense interest in the incretin field.